comprehensive -WSS

comprehensive

author：comprehensive 2025-08-19 04:32:36 - browse：659

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Patients, digital health players weigh in on FTC's data privacy plan

knowledge

focus

WSS

YouTube cracks down on misinformation on cancer treatment

Coloradans with cystic fibrosis could lose access to Trikafta

Bill would allow buprenorphine prescription for addiction via telehealth

Maui wildfire now ranks as the fifth

Gene therapy’s promise and the high cost of hope

Senators push IRS to launch nonprofit hospital probe

hotspot

comprehensive

focus

Drug repurposing or repositioning? The language matters

Bill would allow buprenorphine prescription for addiction via telehealth

Guidelines to prevent youth baseball injuries need more muscle

Medicare proceeds with plan to claw back hospital funds

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senators push IRS to launch nonprofit hospital probe

Medicare proposal to cover medical devices draws a mixed reaction

Illumina slashes 2023 revenue projections yet again

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lung cancer screening guidelines updated for cigarette smokers

knowledge

Maui wildfire now ranks as the fifth

All of Us, NIH's precision medicine initiative, gets a big boost

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Megan Rapinoe shares emotional post following US Women's World Cup exit

entertainment

knowledge

focus

knowledge